Abstract

The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&D costs are not being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease pathology and are ‘druggable’, is the best starting point for improved productivity.
The seven chapters of this volume describe recent progress towards drugs acting at a range of ‘druggable’ targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the chapters cover G-protein coupled receptors, which has historically perhaps been the most fruitful area for medicinal chemists.
*Presents the latest research in the field of drug discovery
*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirect
Praise for the Series:
"...may the Progress in Medicinal Chemistry series continue its invaluable service..."
--Chemistry and Industry
"... a valuable source of reference"
--British Medical Journal
"...These volumes should be on the shelves of all specialist libraries which claim to cater for chemists, biologists, doctors and pharmacists and should be available to everyone interested in the contemporary controversy about drugs, drug firms and the community."
--Pharmaceutical Journal
"...the consistently high standards for this series have been maintained in the present volume. This volume should certainly take its place next to the previous volumes in this series in libraries devoted to medicinal chemistry and drug research..."
--Journal of Medicinal Chemistry